CM
HRTX icon

Caption Management’s Heron Therapeutics HRTX Stock Holding History

Caption Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Buy
+313,681
New +$363K ﹤0.01% 1316
2025
Q4 		– Sell
-734,297
Closed -$907K – 1799
2025
Q3 		$925K Buy
+734,297
New +$1.16M 0.01% 1134
2022
Q2 		– Sell
-36,500
Closed -$209K – 1613
2022
Q1 		$209K Sell
36,500
-312,610
-90% -$2.29M ﹤0.01% 1266
2021
Q4 		$3.19M Buy
+349,110
New +$3.56M 0.04% 616
2021
Q2 		– Sell
-37,000
Closed -$600K – 1416
2021
Q1 		$600K Buy
+37,000
New +$660K 0.01% 775
2020
Q2 		– Sell
-82,400
Closed -$1.35M – 1049
2020
Q1 		$967K Buy
+82,400
New +$1.55M 0.05% 410
2019
Q4 		– Sell
-78,650
Closed -$1.46M – 920
2019
Q3 		$1.46M Buy
78,650
+53,650
+215% +$987K 0.08% 305
2019
Q2 		$465K Sell
25,000
-12,200
-33% -$244K 0.02% 492
2019
Q1 		$909K Buy
+37,200
New +$974K 0.05% 374

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Caption Management's HRTX Position: Q1 2026 in Review

Caption Management opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 313,681 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #1316 among its holdings. This is a return to the name: Caption Management previously reported a position in HRTX as recently as Q3 2025.

Caption Management first reported a position in HRTX in Q1 2019 and has held it in 9 quarters since. The position peaked at $3.19M in Q4 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Caption Management held 313,681 shares of Heron Therapeutics worth $251K as of Q1 2026.
  • Heron Therapeutics was a new Caption Management position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1316 holding.
  • Caption Management first reported a position in Heron Therapeutics in Q1 2019 and has held it in 9 quarters since.
  • Caption Management's Heron Therapeutics position peaked at $3.19M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.